Beta Drugs Ltd. · NSE:BETA
Beta Drugs — Investor Presentation (July 2026)
39 slides from Beta Drugs's investor presentation, Jul 27, 2026
Slide 1: Investor Presentation July 2026
Investor Presentation July 2026 1
Slide 2: Beta Drugs at a Glance: Scale, Reach and Sustained Financial Strength
Beta Drugs at a Glance: Scale, Reach and Sustained Financial Strength 20+ 26+ 246+ 3 Countries Served State-of-the-art Years of Experience Global Clients Manufacturing facilities Globally 280+ 220+ 2 66+ Dossiers Registered Specialty Therapies SKU’s Territory Managers Globally (Oncology & IVF) 27% 2
Slide 3: Company Overview
Company Overview 3
Slide 4: Company Overview: Building a Diversified Specialty Pharma Franchise
Company Overview: Building a Diversified Specialty Pharma Franchise • Established in 2005 as part of the Adley Group, by Mr. Vijay Kumar Batra, Consolidated Revenue (INR Mn) & EBITDA Margin (%) Beta Drugs Ltd. (BETA) is a specialty pharmaceutical company dedicated 3,848 3,624 to improving cancer car
Slide 5: Business Verticals: A Diversified Revenue Mix Across Four Pillars
Business Verticals: A Diversified Revenue Mix Across Four Pillars Domestic Branded Formulations 36% Exports CMO API Revenue Contribution 18% 39% 7% Revenue Revenue Revenue Contribution Contribution Contribution Oncology IVF* Dermatology * IVF revenues has been consolidated in the Domestic Branded Fo
Slide 6: Globally Accredited Manufacturing Facilities with Large Installed Capacities
Globally Accredited Manufacturing Facilities with Large Installed Capacities Beta Drugs Ltd India Formulation Adley Lab India API Plant Adley Formulations India Plant Formulation Plant Certifications: Certifications: Certifications: Location: Nandpur, Solan, Himachal Location: Derabassi, Location: B
Slide 7: Robust R&D Capabilities Supporting Future Growth
Robust R&D Capabilities Supporting Future Growth 80 13 25% 2 Total Products Developed New Products Patents Products in FY25 &FY26 Contribution in FY26 • BETA is among the select Indian oncology pharmaceutical companies that has strong commitment to research, innovation and product development. Track
Slide 8: Strong Global Presence Across Diverse Geographies
Strong Global Presence Across Diverse Geographies LATAM MENA Africa APAC • Belize • Algeria • Ethiopia • India • Brazil • Azerbaijan • Ivory De • Kazakhstan • Caracas • Belarus Cote • Mangolia • Chile • Egypt • Kenya • Myanmar • Columbia • Georgia • Nigeria • Nepal • Costa Rica • Jordan • Tanzania •
Slide 9: Key Milestones in the Company's Growth Journey
Key Milestones in the Company's Growth Journey 1985 2007 2011 2015 2017 2025 Laid the Entered into Foray into Developed • Received SME • Awarded in Forbes foundation of Oncology the in-house Excellence Award Under a billion for 3 Adley Group by Market international Albumin • Listed in NSE SME consec
Slide 10: Seasoned Leadership Team Driving Strategy, Growth and Governance
Seasoned Leadership Team Driving Strategy, Growth and Governance Mr. Rahul Mr. Varun Mr. Ashutosh Batra Batra Shukla Chairman and Managing Director Joint Managing Director Executive Director He holds Master of Science degree in Business and He is the Joint Managing Director of our Company. He is a d
Slide 11: Independent Board Of Directors: Strong Governance and Oversight
Independent Board Of Directors: Strong Governance and Oversight Mr. Sanjay Mr. Ajay Mrs. Monica Sehgal Mahipal Jain Independent Director Independent Director Independent Director He is a Post graduate in Commerce, having approx He is a Partner at HealthQuad, overseeing She is M.S.Ophthalmologist in
Slide 12: Industry Recognition Reflecting a Track Record of Trust and Growth
Industry Recognition Reflecting a Track Record of Trust and Growth Innovative Zone Forbes Asia "Best State Export Award NSE Listing Certificate of Under A Billion" Memento Ceremony Bell Appreciation - The Recognition for Three Memento Most Trusted Consecutive Years Companies to Watch (2023, 2024 & 2
Slide 13: Business Overview
Business Overview 13
Slide 14: Branded Oncology Portfolio: Driving Growth and Market Expansion
Branded Oncology Portfolio: Driving Growth and Market Expansion 180+ 8 85%+ Revenue (INR Mn) Oncology Focused Products under Reach Across India's Corporate & SKUs development Government Hospitals 1,232 1,030 • BETA stands as a premier manufacturer of a wide range of oncology products, including key
Slide 15: Trusted Partner to India's Leading Healthcare Institutions
Trusted Partner to India's Leading Healthcare Institutions 15
Slide 16: Broad-Based Oncology Product Portfolio
Broad-Based Oncology Product Portfolio Adcarb Adcist Adcumin Adpaxil Adplatin Kabonib Kynolib Pazotab AB-Pacli Adbiron Adgef Adlante Adtrinib Adxate Adthal Adben 16
Slide 17: IVF: Tapping into the Growing Opportunity in Assisted Reproductive Care
IVF: Tapping into the Growing Opportunity in Assisted Reproductive Care • BETA entered the high-growth IVF segment through the acquisition of a 66.09% Nivian Revenue (INR Mn) stake in Nivian Lifesciences Pvt. Ltd. in April 2026. 430 • The company is diversifying beyond oncology with a focused portfo
Slide 18: Comprehensive Branded Dermatology Product Portfolio
Comprehensive Branded Dermatology Product Portfolio 40+ 9 Dermatology Focused Products under Revenue (INR Mn) SKU’s development 166 • BETA is expanding presence in the dermatology market with a growing portfolio of specialized skin 123 care solutions. • Catering to a wide spectrum of skin health and
Slide 19: CMO: Most trusted CMO Partner in India Catering to Marquee Customers
CMO: Most trusted CMO Partner in India Catering to Marquee Customers 104+ 14 95% No of Projects under Repeat Business from Clients development Key Customers Revenue (INR Mn) • BETA is one of India's leading oncology-focused CMO partners, serving marquee pharmaceutical companies. 1,475 1,494 1,400 •
Slide 20: API: Backward Integration Provides Significant Lever for Future Margin Expansion
API: Backward Integration Provides Significant Lever for Future Margin Expansion 3 70% APIs under API for formulations development manufactured in-house • BETA has wide portfolio of API related to Oncology drugs supporting both captive consumption and external sales. Revenue (INR Mn) • API business
Slide 21: Strategic Overview
Strategic Overview 21
Slide 22: Distinct Competitive Strengths Support Sustainable Business Growth
Distinct Competitive Strengths Support Sustainable Business Growth Oncology Specialist with Strong Brand Strong Backward Integration Advantage Equity 80%+ API are used for Inhouse Formulations, Established oncology-focused pharmaceutical enabling better cost control, quality assurance company with a
Slide 23: BETA VISION 2030: Strategic Transformation Creating Enduring Value
BETA VISION 2030: Strategic Transformation Creating Enduring Value FY21 FY26 FY30 Other, 6% Other, 7% Other, 6% Domestic Domestic CMO, Branded Branded 13% Domestic Formulations, 28% Formulations Branded CMO, , 36% Formulations, CMO, Exports, 39% Exports, 51% 50% 16% Exports 30% , 18% Key Strategic P
Slide 24: Industry Overview
Industry Overview 24
Slide 25: Pharmaceutical Market Outlook: Expanding Opportunities in India & Overseas
Pharmaceutical Market Outlook: Expanding Opportunities in India & Overseas Global Market Segmentation: Global Pharma Market (USD Tn) Particulars CY 2024 CY 2029P CAGR ~6% CAGR North America 45% 44-45% 5.5-6.5% 2.10-2.20 Europe 26% 25-26% 5-6% APAC 22% 22-23% 6-7% 1.58 1.46 1.49 MENA 3% 2-3% 4.5-5.5%
Slide 26: Oncology: Tapping into the World's Fastest-Growing Pharma Segment
Oncology: Tapping into the World's Fastest-Growing Pharma Segment 20 Mn 0.7 Mn 56% 1.8x New cancer cases globally New cancer cases every year in Global Market Share in Onco vs Pharma Growth 2022 India Cancer Treatment in 2025 Globally Growth Drivers for Indian Oncology Market: Global Oncology Market
Slide 27: Dermatology & IVF: Capitalising on Rising Demand for Specialised Therapies
Dermatology & IVF: Capitalising on Rising Demand for Specialised Therapies Growth Drivers for Indian IVF Market: Indian IVF Market Size (USD Bn) • Fertility rate in India is at 1.9 below the replacement levels, accelerating the need for 15% CAGR fertility interventions. 3.46 • Rising prevalence of i
Slide 28: Q1-FY27 Financial Performance
Q1-FY27 Financial Performance
Slide 29: Q1-FY27 Consolidated Financial Performance
Q1-FY27 Consolidated Financial Performance Revenue (INR Mn) EBITDA (INR Mn) & EBITDA PAT (INR Mn) & PAT Margins (%) Margins (%) 13.15% 1,255 21.83% 11.68% 165 1,002 9.57% 940 274 117 197 90 177 19.66% 18.83% Q1-FY26 Q4-FY26 Q1-FY27 Q1-FY26 Q4-FY26 Q1-FY27 Q1-FY26 Q4-FY26 Q1-FY27 29
Slide 30: Q1-FY27 Segmental Performance
Q1-FY27 Segmental Performance Branded Revenue (INR Mn) Exports Revenue (INR Mn) Contract Manufacturing Revenue (INR Mn) 474 481* 151 361 337 315 323 330 224 155 172 Q1-FY26 Q4-FY26 Q1-FY27 Q1-FY26 Q4-FY26 Q1-FY27 Q1-FY26 Q4-FY26 Q1-FY27 Active Pharmaceutical Dermatology Revenue (INR Mn) Ingredients
Slide 31: Q1-FY27 Operational Highlights
Q1-FY27 Operational Highlights • Branded Oncology business continued to deliver stellar performance delivering growth of 47% y-o-y recording sales of INR 330 Mn on the back of improved performance from existing products and increasing acceptance of our new launches last year. • Contract Manufacturin
Slide 32: Quarterly Consolidated Income Statement
Quarterly Consolidated Income Statement Particular (INR Mn) Q1-FY27 Q1-FY26 Y-o-Y Q4-FY26 Q-o-Q Revenue from Operations 1,255 1,002 25.2% 940 33.5% Operating Expenses 981 805 21.9% 763 28.6% EBITDA 274 197 39.1% 177 54.8% EBITDA Margins (%) 21.83% 19.66% 217 Bps 18.83% 300 Bps Depreciation 43 37 16.
Slide 33: Historical Financial Overview
Historical Financial Overview 33
Slide 34: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particular (INR Mn) FY24 FY25 FY26 Q1-FY27 Revenue from Operations 2,957 3,624 3,848 1,255 Operating Expenses 2,357 2,878 3,091 981 EBITDA 600 746 757 274 EBITDA Margins (%) 20.29% 20.58% 19.67% 21.83% Depreciation 98 125 172 43 Finance Cost 28 70 153 26 Othe
Slide 35: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Particular (INR Mn) FY24 FY25 FY26 Particular (INR Mn) FY24 FY25 FY26 Equity Non-current Assets A) Property, Plant And Equipment A) Equity Share Capital 96 101 101 I) Property, Plant And Equipment 592 804 1,154 B) Other Equity 1,475 1,870 2,346 II) Intangible As
Slide 36: Consolidated Historical Financial Trend
Consolidated Historical Financial Trend Revenues from Operations (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 3,848 3,624 746 757 424 415 2,957 600 364 21.83% 1,255 165 274 20.29% 20.58% 19.67% 12.31% 11.70% 10.78% 13.15% FY24 FY25 FY26 Q1-FY27 FY24 FY25 FY26 Q1-FY27
Slide 37: Capital Market Data
Capital Market Data 40.0% 1-Year Stock Performance up to 30th June 2026 20.0% 0.0% -20.0% -40.0% Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 -60.0% Beta Drugs Nifty Price Data (As on 30th June 2026) Shareholding Pattern (As on 30th June 2026) Face Value (INR)
Slide 38: Disclaimer
Disclaimer Beta Drugs Ltd. Disclaimer: No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all ev
Slide 39: Thank You
Gd BETA Thank Y@u